Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study Of Adults And Adolescents With Vasomotor Rhinitis

ClinicalTrials.gov ID: NCT00117325

Public ClinicalTrials.gov record NCT00117325. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 2:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 4 Week Randomized, Double Blind, Placebo Controlled Study of GW685698X Aq Nasal Spray 100mcg QD in Adults and Adolescents With Vasomotor Rhinitis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of this study is to compare the efficacy and safety of GW685698X 100mcg once daily (QD) aqueous nasal spray with vehicle placebo nasal spray in adult and adolescent subjects (12 years of age and older) with vasomotor rhinitis (VMR).

Study identification

NCT ID
NCT00117325
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
352 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 11, 2005 (Actual)
Primary completion
Feb 9, 2006 (Actual)
Completion
Feb 9, 2006 (Actual)
Last update posted
Mar 13, 2018

2005 – 2006

United States locations

U.S. sites
38
U.S. states
19
U.S. cities
37
Facility City State ZIP Site status
GSK Investigational Site Beverly Hills California 90212 —
GSK Investigational Site Huntington Beach California 92647 —
GSK Investigational Site Mission Viejo California 92691 —
GSK Investigational Site San Diego California 92120 —
GSK Investigational Site San Diego California 92123 —
GSK Investigational Site Santa Barbara California 93105 —
GSK Investigational Site Colorado Springs Colorado 80907 —
GSK Investigational Site Englewood Colorado 80112 —
GSK Investigational Site Fort Collins Colorado 80526 —
GSK Investigational Site Woodstock Georgia 30188 —
GSK Investigational Site Chicago Illinois 60637 —
GSK Investigational Site Evansville Indiana 47713 —
GSK Investigational Site Louisville Kentucky 40207 —
GSK Investigational Site Covington Louisiana 70433 —
GSK Investigational Site Shreveport Louisiana 71104 —
GSK Investigational Site Bangor Maine 04401 —
GSK Investigational Site Baltimore Maryland 21236 —
GSK Investigational Site Rockville Maryland 20850 —
GSK Investigational Site Novi Michigan 48375 —
GSK Investigational Site Ypsilanti Michigan 48197 —
GSK Investigational Site Minneapolis Minnesota 55402 —
GSK Investigational Site Mount Laurel New Jersey 08054 —
GSK Investigational Site Liverpool New York 13088 —
GSK Investigational Site Rochester New York 14618 —
GSK Investigational Site Canton Ohio 44718 —
GSK Investigational Site Cincinnati Ohio 45231 —
GSK Investigational Site North Olmsted Ohio 44070 —
GSK Investigational Site Lake Oswego Oregon 97035 —
GSK Investigational Site Portland Oregon 97213 —
GSK Investigational Site Easton Pennsylvania 18042 —
GSK Investigational Site Palmyra Pennsylvania 17078 —
GSK Investigational Site Pittsburgh Pennsylvania 15213 —
GSK Investigational Site Upland Pennsylvania 19013 —
GSK Investigational Site Charleston South Carolina 29407 —
GSK Investigational Site Orangeburg South Carolina 29118 —
GSK Investigational Site Germantown Tennessee 38138 —
GSK Investigational Site Knoxville Tennessee 37922 —
GSK Investigational Site Salt Lake City Utah 84102 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00117325, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 13, 2018 · Synced Nov 9, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00117325 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →